Skip to content
City Confidential
 
Sorting the Bulls from the Bears - Tips & Insight into the UK Stock Markets
  • Home
  • Markets
    • Main Market
    • AIM Market
  • Penny Share Picks
  • The Trader
  • Newsletter
  • Companies
    • A-B
      • Abingdon Health [ABDX]
      • Angle [AGL]
      • Alumasc [ALU]
      • Aston Martin Lagonda [AML]
      • Anpario [ANP]
      • Alliance Pharma [APH]
      • Avacta [AVCT]
      • Brave Bison [BBSN]
      • Barratt [BDEV]
      • Bloomsbury Publishing [BMY]
      • Audioboom [BOOM]
      • British Petroleum [BP]
    • C-D
      • Carclo [CAR]
      • Carr’s Group [CARR]
      • Capita [CPI]
      • Coral Products [CRU]
      • Duke Royalty [DUKE]
    • E-F
      • Everyman Media [EMAN]
      • Essentra [ESNT]
      • Funding Circle Holdings [FCH]
      • Finsbury Food Group [FIF]
      • Flowtech Fluidpower [FLO]
      • Filtronic [FTC]
    • G-H
      • Getbusy [GETB]
      • Glaxosmithkline [GSK]
      • Halfords Group [HFD]
      • Hargreaves Services [HSP]
      • HSS Hire Group [HSS]
    • I-J
      • Investec [INVP]
      • International Personal Finance [IPF]
      • ITV [ITV]
      • Jet2 [JET2]
      • Journeo [JNEO]
      • Johnson Service Group [JSG]
    • K-L
      • Kier Group [KIE]
      • Logistics Development [LDG]
      • Lloyds Banking [LLOY]
      • LPA Group [LPA]
    • M-N
      • Marston’s Group [MARS]
      • Michelmersh Brick Holdings [MBH]
      • Manx Financial Group [MFX]
      • Meggitt [MGGT]
      • Marks & Spencer Group [MKS]
      • Minds + Machines Group [MMX]
      • Melrose Industries [MRO]
      • MS International [MSI]
      • Mitie Group [MTO]
      • Northern Bear [NTBR]
      • NFW Group [NWF]
    • O-P
      • Omega Diagnostics Group [ODX]
      • Palace Capital [PCA]
      • Pets at Home Group [PETS]
      • Premier Foods [PFD]
      • Brighton Pier Group [PIER]
      • Premier Miton Group [PMI]
      • Portmeirion [PMP]
      • Pressure Technologies [PRES]
    • Q-R
      • Robinson [RBN]
      • RIT Capital Partners [RCP]
      • Rio Tinto [RIO]
      • Rank Group [RNK]
      • Renold [RNO]
    • S-T
      • Sansbury [SBRY]
      • Speedy Hire [SDY]
      • WH Smith [SMWH]
      • Senior [SNR]
      • Synectics [SNX]
      • Serco Group [SRP]
      • Staffline Group [STAF]
      • STM Group [STM]
      • Sutton Harbour Group [SUH]
      • Surgical Innovations [SUN]
      • Synthomer [SYNT]
      • Tandem Group [TND]
      • Titon Holdings [TON]
      • Town Centre Securities [TOWN]
      • Tristel [TSTL]
      • TT Electronics [TTG]
    • U-V
      • Unilever [ULVR]
      • UP Global [UPGS]
      • Virgin Wines UK [VINO]
      • Vianet Group [VNET]
      • Vodafone Group [VOD]
      • The Vitec Group [VTC]
      • Vitec [VTEC]
      • Vertu Motors [VTU]
    • W-Z
      • Xeros Technologies Group [XSG]
      • Zoo Digital Group [ZOO]
      • Zytronic [ZYT]
  • Portfolios
    • Trader Portfolio 2
  • Insight & Ideas
  • TRY
  • More
      • Lost Password?
    • Search
    • Follow us:
    • Twitter
    • Email
    • More
    • Menu
    City Confidential
     
    Sorting the Bulls from the Bears - Tips & Insight into the UK Stock Markets
    • Search
    AIM Market Free TipFree Featured Company

    Free share tips: Clinigen (CLIN) – 586p

    by Simon Flather21 July 202121 July 2021
    • Share
    • Tweet
    • Pin it
    • Share
    • Email
    • More

    Free share tips posted weekly! This week’s free share tip is Clinigen. We believe that shares in AIM-listed Clinigen are worth a look following the recent weakness in the share price.  The company issued a profit warning last month and this resulted in a fall in the share price of around a quarter to 615p as investors were taken by surprise.  The pandemic has delayed clinical trials and has also delayed cancer treatments resulting in a sharp reduction in profit forecasts for the year.  However, last week the company provided another update on trading for the financial year that ended on 30 June and this contained no new surprises.  The new financial year which has just started is expected to see a return to growth and so the 2021 financial year could prove to be the low point in the group’s fortunes.

    Clinigen is an AIM-listed global, specialist pharmaceutical services and products group which operates globally with sites in North America, Europe, Africa and the Far East.  The group operates through two divisions.  The products business includes the cancer drug Proleukin, which is administered in hospitals, and demand for this has fallen due to delays to oncology treatment.  Sales of this are only likely to increase when hospital and cancer centre services return to normal.

    The company also has other drugs which it supplies although these are less important.  It is also rolling out a new drug to treat leukaemia called Erwinase although this was only made available in April.  The services business provides packaging, logistics and other services to pharmaceutical companies, operating with 34 of the top 50 global companies.

    Related

    • cityconfidential Newsletter April 2025

    In the most recent statement, the company confirmed that revenues in the year to 30 June were £455m, an increase of 12% excluding discontinued activities.  Adjusted pre-tax profits are likely to fall to £93m from £108m last year with earnings per share on the same basis falling to around 55p from 65.6p.  This puts the shares on a modest p/e ratio of just 10.7x and with earnings per share likely to rise to 57p in the current financial year this falls yet further.

    The annual dividend of 7.61p per share is nothing to shout about but the group continues to reduce debt as it generates cash.  Despite spending £15m on the roll out of Erwinase in the second half of the year, net debt is expected to have fallen by £13m to £317m during the period.  This can be expected to fall further in the current year.

    Although the shares are currently out of favour, they look cheap on fundamental grounds and the current valuation could make the company attractive to a predator.  We have highlighted the high levels of corporate activity elsewhere on the website and the healthcare sector has not avoided this with bids for Vectura and UDG Healthcare.  Our free share tip is therefore BUY.

    Read more of our free share tips here.

    Tagged: aim share tips BUY CLIN

    Related Stories

    • cityconfidential Newsletter April 2025

      17 April 202517 April 2025
    • cityconfidential Newsletter March 2025

      20 March 2025
    • cityconfidential Newsletter February 2025

      20 February 202520 February 2025
    • cityconfidential Newsletter January 2025

      16 January 2025
    • cityconfidential Newsletter December 2024

      12 December 202412 December 2024
    • cityconfidential Newsletter November 2024

      14 November 2024
    • cityconfidential Newsletter October 2024

      17 October 202417 October 2024
    • cityconfidential Newsletter September 2024

      19 September 2024

    Post navigation

    Previous Story DX Group – 32.5p
    Next Story The 600 Group – 13.5p

    News

    • Main Market
    • AIM Market
    • Penny Stocks
    • The Trader

    About

    • Contact
    • T&Cs
    • Privacy
    • Wealth Warning

    Membership

    • Subscribe
    • Your Account

     

    01943 600 644  |  info@cityconfidential.co.uk
    1 Skipton Road, Ilkley, West Yorkshire, LS29 9EH

    Please note, live feed data is subject to a 15 minute delay.

    BrokerLink | © Independent Financial Publications. All Rights Reserved. | Westbrook Agency
    City Confidential
     
    Sorting the Bulls from the Bears - Tips & Insight into the UK Stock Markets
    • Subscribe
    • Your Membership
    • Home
    • Newsletter
    • Main Market
    • AIM Market
    • Penny Share Picks
    • The Trader
    • Trader Portfolio 2
    • Insight & Ideas
    • Contact
    This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT